Early stem-cell transplantation and ongoing therapy led to survival benefits for patients with newly diagnosed multiple myeloma, according to data reported at the European Hematology Association meeting in Milan. Another presentation at the EHA meeting showed a twofold increase in the time to first relapse (PFS1) with continuous versus fixed-duration therapy.

READ FULL ARTICLE Curated publisher From Medical Page Today